Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 18:04:44时区推断·⟳ 抓取 18:05:15·⚡ 决策 07-27 18:06:59 +1m44s·92.2 天前
IDEAYA启动IDE892单药扩展队列，但此前已预告且无疗效数据
IDE892进入MTAP缺失NSCLC和胰腺癌单药扩展队列，说明剂量递增已达到公司认为有效的人体暴露水平，但这仍是早期临床进展。
📄 原文Investing.com↗ 原文
IDEAYA initiates expansion phase for cancer drug IDE892
Oil prices tumble over 8% amid halt to fighting between U.S., Iran SOUTH SAN FRANCISCO - IDEAYA Biosciences (NASDAQ:IDY…
不做 IDEAYA Biosciences（IDYA.US）
不做：IDE892启动单药扩展是早期临床程序性进展，6月已预告Q3启动，且未披露疗效或商业化量级数据，缺少足够短线edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司3月已披露IDE892进入Phase 1剂量递增，并说明MTAP缺失NSCLC和PDAC是目标适应症。
- 公司已预告IDE892单药扩展预计在2026年三季度启动，并披露本次新闻中的关键药物属性和MTAP患病率信息。
- Investing.com报道IDEAYA启动Part 2单药扩展队列，属于既定临床路径推进。市场反应:事件发生时美股盘前，连续交易未开。
关键理由
- IDE892进入MTAP缺失NSCLC和胰腺癌单药扩展队列，说明剂量递增已达到公司认为有效的人体暴露水平，但这仍是早期临床进展。
- 6月15日公司已公开预告IDE892单药扩展预计在2026年三季度启动，本次更像按计划执行而非全新超预期读数。
- IDEAYA当前无商业化收入，IDE892仍处Phase 1/2且未披露ORR、DoR、PFS等疗效数据，短线重定价量级难以量化。
主要风险
- 若后续R&D Day或组合试验披露真实疗效数据，事件性质会从程序性进展升级为临床数据催化。
- 小中型biotech盘前新闻流动性较低，早期管线标题可能引发短线波动但持续性不足。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-15 · 影响 weakens
公司此前已明确预告单药扩展将在Q3启动，削弱今天新闻的新鲜度。
检索:IDEAYA IDE892 monotherapy expansion anticipated Q3 2026 June 15 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-27 · 影响 weakens
本次新闻未披露客观缓解率、剂量限制毒性或生存终点等可驱动biotech重估的疗效数据。
检索:IDEAYA IDE892 clinical data objective response rate Phase 1 PRMT5 inhibitor 原文 ↗
原文全文
展开原文 · 2,055 字
Oil prices tumble over 8% amid halt to fighting between U.S., Iran
SOUTH SAN FRANCISCO - IDEAYA Biosciences (NASDAQ:IDYA) announced today the initiation of Part 2 monotherapy expansion in its Phase 1/2 clinical trial evaluating IDE892, a PRMT5 inhibitor, in MTAP-deleted solid tumors, focusing on non-small cell lung cancer and pancreatic ductal adenocarcinoma.
The company stated that the expansion was initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved. The maximum tolerated dose has not yet been reached in the ongoing dose escalation, according to the press release statement.
IDE892 demonstrates 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding. The drug has a CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the seven major cytochrome P450 enzymes.
"We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
The company is conducting combination studies with IDE892 and IDE397, its MAT2A inhibitor, in MTAP-deleted NSCLC and PDAC. IDEAYA also entered into a clinical collaboration with Roche evaluating IDE892 in combination with RG6505, Roche’s pan-RAS inhibitor, in MTAP-deleted pancreatic ductal adenocarcinoma. The company targets first-patient-in for the IDE892 and pan-RAS combination in the second half of 2026.
MTAP deletion is estimated to occur in up to 40% of pancreatic ductal adenocarcinoma and approximately 15% of non-small cell lung cancer. There are currently no approved therapies for MTAP-deleted cancers.
IDEAYA is advancing a CDKN2A program through preclinical toxicology studies, targeting an investigational new drug application in the first half of 2027. The company plans to host a MTAP/CDKN2A, KRAS, and Pancreatic Cancer R&D Day in the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SOUTH SAN FRANCISCO - IDEAYA Biosciences (NASDAQ:IDYA) announced today the initiation of Part 2 monotherapy expansion in its Phase 1/2 clinical trial evaluating IDE892, a PRMT5 inhibitor, in MTAP-deleted solid tumors, focusing on non-small cell lung cancer and pancreatic ductal adenocarcinoma.
The company stated that the expansion was initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved. The maximum tolerated dose has not yet been reached in the ongoing dose escalation, according to the press release statement.
IDE892 demonstrates 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding. The drug has a CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the seven major cytochrome P450 enzymes.
"We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
The company is conducting combination studies with IDE892 and IDE397, its MAT2A inhibitor, in MTAP-deleted NSCLC and PDAC. IDEAYA also entered into a clinical collaboration with Roche evaluating IDE892 in combination with RG6505, Roche’s pan-RAS inhibitor, in MTAP-deleted pancreatic ductal adenocarcinoma. The company targets first-patient-in for the IDE892 and pan-RAS combination in the second half of 2026.
MTAP deletion is estimated to occur in up to 40% of pancreatic ductal adenocarcinoma and approximately 15% of non-small cell lung cancer. There are currently no approved therapies for MTAP-deleted cancers.
IDEAYA is advancing a CDKN2A program through preclinical toxicology studies, targeting an investigational new drug application in the first half of 2027. The company plans to host a MTAP/CDKN2A, KRAS, and Pancreatic Cancer R&D Day in the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。